INMED PHARMACEUTICALS INC. Form PRE 14A: Preliminary proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-10-24: Form PRE 14A; Period of report 2025-10-24; Description PRELIMINARY PROXY STATEMENT; Document ea0262456-pre14a_inmed.htm.
- 2025-04-29: Form PRE 14A; Period of report 2025-04-29; Description PROXY STATEMENT; Document ea0239463-01.htm.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
|---|
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
|---|
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
|---|
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
|---|